Pfizer, BMS oral anti-clot drug shows promise

Pfizer and Bristol-Myers Squibb's oral anticoagulant apixaban achieved positive results in a late-stage Advance-2 study. Apixaban was shown to be statistically superior to 40 mg once daily enoxaparin (Lovenox) in reducing the incidence of venous thromboembolism in patients undergoing total knee replacement surgery. The study results also showed lower rates of bleeding in patients treated with apixaban compared to enoxaparin. BMS release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.